Clinical Trial Update: Open-Label Safety Study of AXS-05 in Subjects With Depression [Phase 3]

View source ↗

Summary

Open-label safety study of AXS-05 in subjects with depression completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Major Depressive Disorder, Treatment Resistant Depression | Phase 3 | Status: COMPLETED | Results posted: 2022-10-12